Matthew Spinelli, Megan J. Heise, David V. Glidden, Janet Grochowski, Jon Oskarsson, Larisa Niles-Carnes, Eudiah Ochieng, Meredith Lora, Amalia Aldredge, Nathanael Gistand, Chesa Cox, Jonathan Colasanti, Monica Gandhi, Lauren F. Collins
Long-acting cabotegravir/rilpivirine supports virologic suppression among people with HIV (PWH) facing adherence challenges. In two large U.S. cohorts(n=1,070), 96% of viremic PWH achieved virologic suppression at a 4-week median. However, blips/failure were more frequent among PWH initiating with viremia, underscoring the need for careful monitoring and optimization of long-acting treatment.